Web 2.0 for Pharma Innovation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Web 2.0 for Pharma Innovation
Internal and external Web-based communities are changing how pharma companies can innovate.


Pharmaceutical Technology
Volume 35, Issue 9, pp. 14


Patricia Van Arnum
Innovation. Any company looks to new products and services to drive value and competitive advantage. Our emphasis in innovation typically focuses on what is made new or improved, but not on how we innovate. In facing shortfalls in achieving innovation, one may ask: "Was the problem the idea or the process used to generate the idea?" The short answer: it is both.

The practical ways to improve innovation in sourcing/procurement was discussed at a recent educational program of the Drug, Chemical, and Associated Technologies Association. Pharmaceutical companies, their suppliers, and other experts shared ways on how to cultivate and systemize innovation for generating actionable ideas for new or improved processes, products, or services, a particularly challenging task in sourcing/ procurement, where cost reduction is a primary and restrictive emphasis.

An interesting thread in this dialogue was the growing use among pharma companies of "innovation communities." These communities consist of employees in multiple functional areas, suppliers, customers, and other stakeholders that use Web-based platforms as a means to share ideas, information, and lessons learned. The premise is simple but important: engage people, internally and externally, in a structured, but accessible way to cultivate innovation.

A model for open innovation is Procter & Gamble's (P&G) "Connect + Develop" platform. According to P&G, more than 50% of its product initiatives involve collaboration from outside innovators. For pharma companies rethinking their innovation strategy, consider inside–outside innovation enabled by Web 2.0.

For additional insight, see "Strategies for Innovation in Pharmaceutical Sourcing and Procurement," at http://PharmTech.com/strategiesinnovation and "Innovation in Sourcing" at http://PharmTech.com/strategiesinnovation.

Patricia Van Arnum is a senior editor of Pharmaceutical Technology.

Read Patricia's blogs at http://blog.PharmTech.com/

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
29%
Restricts innovation and the development of new drugs.
54%
Has no impact on drug development.
4%
Do not know.
13%
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology,
Click here